WO2000012110A3 - Use of anti(w)pressor agents for vascular remodeling in genital dysfunction - Google Patents

Use of anti(w)pressor agents for vascular remodeling in genital dysfunction Download PDF

Info

Publication number
WO2000012110A3
WO2000012110A3 PCT/CA1999/000787 CA9900787W WO0012110A3 WO 2000012110 A3 WO2000012110 A3 WO 2000012110A3 CA 9900787 W CA9900787 W CA 9900787W WO 0012110 A3 WO0012110 A3 WO 0012110A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
administered
receptor antagonists
pressor
pressor agent
Prior art date
Application number
PCT/CA1999/000787
Other languages
French (fr)
Other versions
WO2000012110A2 (en
Inventor
Michael A Adams
Jeremy P W Heaton
Original Assignee
Univ Kingston
Michael A Adams
Jeremy P W Heaton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kingston, Michael A Adams, Jeremy P W Heaton filed Critical Univ Kingston
Priority to AU54034/99A priority Critical patent/AU5403499A/en
Priority to CA002340206A priority patent/CA2340206A1/en
Priority to EP99939874A priority patent/EP1235563A2/en
Publication of WO2000012110A2 publication Critical patent/WO2000012110A2/en
Publication of WO2000012110A3 publication Critical patent/WO2000012110A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Abstract

The present invention provides a method of administration of an agent which acts to remodel neuronal or vascular pathways for the long term management of sexual dysfunction in both males and females. In a preferred embodiment, the invention provides a method of ameliorating or reversing pathogenic vascular degradative modeling in the ilio-hypogastric-pudental arterial bed and genitalia comprising administering to a human patient in need of such treatment a therapeutically effective amount of an anti-pressor agent. The anti-pressor agent comprises one or more compounds selected from the therapeutic classes of direct vasodilators such as hydralazine and NO donors, ACE inhibitors, angiotensin-II receptor antagonists, α1-adrenergic receptor antagonists, β-adrenergic receptor antagonists, calcium channel blockers, and phosphodiesterase inhibitors. The anti-pressor agent may be co-administered with a diuretic compound, and is administered either chronically at low dose, or for short periods of time at doses higher than are typically used for the treatment of hypertension. In certain embodiments of the method of the invention, the anti-pressor agent is co-administered with a diuretic agent and/or prostaglandin-E1.
PCT/CA1999/000787 1998-08-26 1999-08-25 Use of anti(w)pressor agents for vascular remodeling in genital dysfunction WO2000012110A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU54034/99A AU5403499A (en) 1998-08-26 1999-08-25 Methods for remodeling neuronal and cardiovascular pathways
CA002340206A CA2340206A1 (en) 1998-08-26 1999-08-25 Use of anti-pressor agents for vascular remodeling in genital dysfunction
EP99939874A EP1235563A2 (en) 1998-08-26 1999-08-25 Use of anti(w)pressor agents for vascular remodeling in genital dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9817898P 1998-08-26 1998-08-26
US60/098,178 1998-08-26

Publications (2)

Publication Number Publication Date
WO2000012110A2 WO2000012110A2 (en) 2000-03-09
WO2000012110A3 true WO2000012110A3 (en) 2000-08-03

Family

ID=22267773

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000787 WO2000012110A2 (en) 1998-08-26 1999-08-25 Use of anti(w)pressor agents for vascular remodeling in genital dysfunction

Country Status (5)

Country Link
US (4) US6284763B1 (en)
EP (1) EP1235563A2 (en)
AU (1) AU5403499A (en)
CA (1) CA2340206A1 (en)
WO (1) WO2000012110A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
ATE315931T1 (en) * 1997-06-23 2006-02-15 Cellegy Pharma Inc MICRODOSIS THERAPY OF VASCULAR DISEASES THROUGH NO-DONORS
US6284763B1 (en) * 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6627632B2 (en) * 1998-12-14 2003-09-30 Cellegy Pharmaceuticals, Inc. Compositions and methods for the treatment of anorectal disorders
US7135498B1 (en) * 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
EP1212053A4 (en) * 1999-09-08 2004-08-11 Nitromed Inc Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7708989B2 (en) * 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) * 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
EP1244455B1 (en) * 1999-10-29 2009-07-22 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
US6900008B2 (en) * 2001-10-31 2005-05-31 Emory University Methods and formulations for minimizing spasticity in blood vessel grafts
KR20030037081A (en) * 2001-11-02 2003-05-12 한국과학기술연구원 Method for the suppression of visceral pain by regulating T-type calcium channel
US7166293B2 (en) * 2002-03-29 2007-01-23 Carlsbad Technology, Inc. Angiogenesis inhibitors
US20050209252A1 (en) * 2002-03-29 2005-09-22 Che-Ming Teng Cancer treatment
WO2003090870A1 (en) * 2002-04-26 2003-11-06 Altana Pharma Ag Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency
US20050119278A1 (en) * 2002-05-16 2005-06-02 Che-Ming Teng Anti-angiogenesis methods
JP2005537822A (en) * 2002-06-28 2005-12-15 ノバルティス アクチエンゲゼルシャフト Use of organic compounds
US8133903B2 (en) * 2003-10-21 2012-03-13 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
ITMI20031428A1 (en) 2003-07-11 2005-01-12 Indena Spa COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE FOR THE TREATMENT OF SEXUAL DYSFUNCTIONS
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
GB0325291D0 (en) * 2003-10-29 2003-12-03 Pfizer Ltd Novel combination
US20050255178A1 (en) * 2004-02-04 2005-11-17 Bloch Kenneth D Enhancing the effectiveness of an inhaled therapeutic gas
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
AU2005274763A1 (en) * 2004-07-16 2006-02-23 Nitromed, Inc. Compositions and methods related to heart failure
US9012454B2 (en) 2005-12-09 2015-04-21 Mayo Foundation For Medical Education And Research Sexual dysfunction
WO2007097951A2 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2007136626A1 (en) * 2006-05-16 2007-11-29 Nitromed, Inc. Solid dosage formulations of hydralazine compounds
EP2037929A4 (en) * 2006-06-02 2010-02-17 Univ San Diego State Res Found Compositions and methods for ameliorating hyperlipidemia
US20090042835A1 (en) * 2006-06-02 2009-02-12 Davis Roger A Compositions and methods for ameliorating hyperlipidemia
FR2921365B1 (en) * 2007-09-21 2012-10-12 Servier Lab NOVEL ADDITIONAL SALTS OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS TO NO DONOR ACIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
CA2704100C (en) * 2007-10-26 2017-07-04 Pacific Therapeutics Ltd. Compositions and methods for treating fibroproliferative disorders
WO2015035308A2 (en) 2013-09-06 2015-03-12 The University Of Montana Method of reducing neuronal cell death with haloalkylamines
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
CA3027368A1 (en) 2016-06-13 2017-12-21 Ascendia Pharmaceuticals, Llc Parenteral sustained-release delivery of carvedilol disperse systems
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028142A1 (en) * 1995-03-14 1996-09-19 Vivus, Incorporated Method and kit for preventing erectile dysfunction
WO1997033608A2 (en) * 1996-03-13 1997-09-18 Queen's University At Kingston Antagonism of endothelin actions
WO1998058633A2 (en) * 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3105849A (en) 1960-02-01 1963-10-01 Ciba Geigy Corp Bicyclic hydrazinium compounds
US4254145A (en) * 1978-08-16 1981-03-03 American Cyanamid Company Topical application of prostaglandin hypotensive agents
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
US5773457A (en) * 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
CA2188385C (en) 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US5658936A (en) 1995-09-18 1997-08-19 Brigham & Women's Hospital, Inc. Enhancement of erectile function with renin-angiotensin system inhibitors
US6251436B1 (en) * 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
SE9600120D0 (en) * 1996-01-15 1996-01-15 Astra Ab Novel medical use
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US6201002B1 (en) * 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US5958884A (en) * 1997-04-11 1999-09-28 The Brigham And Women's Hospital, Inc. Compositions and methods for treating erectile dysfunction
WO1998055447A1 (en) 1997-06-05 1998-12-10 Venantius Limited 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them
EP0986530A1 (en) 1997-06-05 2000-03-22 Venantius Limited Indane compounds and their pharmaceutical use
US5919474A (en) * 1997-10-28 1999-07-06 Vivus, Inc. Transurethral administration of vasoactive agents to treat peripheral vascular disease, related vascular diseases, and vascular impotence associated therewith
US20020013304A1 (en) * 1997-10-28 2002-01-31 Wilson Leland F. As-needed administration of an androgenic agent to enhance female sexual desire and responsiveness
US6197801B1 (en) * 1998-01-14 2001-03-06 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6124461A (en) * 1998-05-26 2000-09-26 Saint Louis University, Health Services Center, Research Administration Compounds, compositions, and methods for treating erectile dysfunction
US6284763B1 (en) * 1998-08-26 2001-09-04 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996028142A1 (en) * 1995-03-14 1996-09-19 Vivus, Incorporated Method and kit for preventing erectile dysfunction
WO1997033608A2 (en) * 1996-03-13 1997-09-18 Queen's University At Kingston Antagonism of endothelin actions
WO1998058633A2 (en) * 1997-06-23 1998-12-30 Queen's University At Kingston Microdose therapy of vascular conditions by no donors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. HYPERTENSON, 12(SUPPL. 4):S37-S42, 1994 *
M. SCHARTL: "Remodeling of myocardium and arteries by chronic angiotensin converting enzyme inhibition in hypertensive patients", FILE BIOSIS, AN=PREV199497466956, XP002137640 *
R.M.K.W. LEE: "Debate: vascular remodeling", J. HYPERTENSION, vol. 15, no. 4, 1997, pages 333 - 337, XP000905246 *

Also Published As

Publication number Publication date
US20030008020A1 (en) 2003-01-09
US6458797B1 (en) 2002-10-01
US20040234619A1 (en) 2004-11-25
US6284763B1 (en) 2001-09-04
CA2340206A1 (en) 2000-03-09
AU5403499A (en) 2000-03-21
US20020035067A1 (en) 2002-03-21
US6787553B2 (en) 2004-09-07
WO2000012110A2 (en) 2000-03-09
EP1235563A2 (en) 2002-09-04

Similar Documents

Publication Publication Date Title
WO2000012110A3 (en) Use of anti(w)pressor agents for vascular remodeling in genital dysfunction
EP2335734A3 (en) Treatment of pain and other alpha 2 adrenergic-mediated conditions
MX2007005570A (en) Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases.
WO2005046318A3 (en) Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
EA200400982A1 (en) METHODS OF TREATMENT OF PATIENTS SUFFERING FROM DISTURBANCE OF MOTION
DK1121111T3 (en) Compounds for the treatment of weight loss
ES2164040T1 (en) USE OF AGONISTS OF THE GLICINE UNION SITE OR INHIBITORS OF GLYCIN ABSORPTION FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS.
EA200000468A1 (en) THERAPEUTIC COMPOSITION FOR THE ADMINISTRATION OF TOLTERODINE WITH CONTROLLED DELIVERY
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2004017896A3 (en) Combination therapy using a dual ppar alpha/gamma agonist and an angiotensin ii type i receptor antagonist
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
EA200001010A1 (en) APPLICATION OF DEXMEDETOMIDINE FOR SEDATIVE IMPACT IN THE DEPARTMENT OF INTENSIVE THERAPY
WO2004006912A3 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
CO5570661A2 (en) COMBINATIONS THAT INCLUDE COX-2 AND ASPIRINE INHIBITORS
MXPA05005781A (en) Combination of ibuprofen and oxycodone for acute pain relief.
PT838223E (en) BRAIN EDEMA INHIBITOR
WO2003015690B1 (en) Method for treating primary insomnia
TW200503683A (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
NO20042758L (en) Procedure for treating a patient requiring analgesia.
PT986393E (en) USING A NITROXIDE OR ITS PRO-PHARMACY IN THE CANCER'S PROFILACTIC AND THERAPEUTIC TREATMENT
DE60204694D1 (en) COMBINATION THERAPY FOR THE TREATMENT OF HEART FAILURE
WO2003103675A3 (en) Combination treatments for purinoceptor-related disorders
GEP201606538B (en) Preoperative treatment of post operative pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2340206

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2340206

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1999939874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939874

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999939874

Country of ref document: EP